The present invention is related to Nox4 inhibitors, pharmaceutical composition thereof and to their use for the treatment and/or prevention of osteoporosis or an osteoclastogenesis dysfunction, in particular osteoporotic and pre-osteoporotic osteoclastogenesis dysfunction.